Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
69.25
-0.26 (-0.37%)
At close: Apr 20, 2026, 4:00 PM EDT
72.10
+2.85 (4.12%)
Pre-market: Apr 21, 2026, 5:25 AM EDT
Arrowhead Pharmaceuticals Employees
Arrowhead Pharmaceuticals had 711 employees as of September 30, 2025. The number of employees increased by 102 or 16.75% compared to the previous year.
Employees
711
Change (1Y)
102
Growth (1Y)
16.75%
Revenue / Employee
$1,534,432
Profits / Employee
$284,480
Market Cap
9.70B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 711 | 102 | 16.75% |
| Sep 30, 2024 | 609 | 84 | 16.00% |
| Sep 30, 2023 | 525 | 128 | 32.24% |
| Sep 30, 2022 | 397 | 68 | 20.67% |
| Sep 30, 2021 | 329 | 97 | 41.81% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,100 |
| Exelixis | 1,077 |
| Axsome Therapeutics | 925 |
| ImmunityBio | 691 |
| Cytokinetics | 673 |
| Vaxcyte | 507 |
| Halozyme Therapeutics | 423 |
ARWR News
- 14 hours ago - Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results - Business Wire
- 23 days ago - Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo - Business Wire
- 7 weeks ago - Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events - Business Wire
- 2 months ago - Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results - Business Wire
- 2 months ago - Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 - PRNewsWire
- 2 months ago - Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia - Business Wire
- 3 months ago - Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results - Business Wire
- 3 months ago - Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants - Business Wire